HK1202299A1 - Novel cancer-associated antigen - Google Patents
Novel cancer-associated antigenInfo
- Publication number
- HK1202299A1 HK1202299A1 HK15102822.3A HK15102822A HK1202299A1 HK 1202299 A1 HK1202299 A1 HK 1202299A1 HK 15102822 A HK15102822 A HK 15102822A HK 1202299 A1 HK1202299 A1 HK 1202299A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- associated antigen
- novel cancer
- cancer
- novel
- antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75196505P | 2005-12-21 | 2005-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202299A1 true HK1202299A1 (en) | 2015-09-25 |
Family
ID=38188229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102822.3A HK1202299A1 (en) | 2005-12-21 | 2015-03-19 | Novel cancer-associated antigen |
Country Status (12)
Country | Link |
---|---|
US (4) | US7956162B2 (xx) |
EP (1) | EP1976987B1 (xx) |
JP (2) | JP5380075B2 (xx) |
CN (2) | CN101400793B (xx) |
AU (1) | AU2006329198B2 (xx) |
CA (1) | CA2633131A1 (xx) |
ES (1) | ES2395103T3 (xx) |
HK (1) | HK1202299A1 (xx) |
IL (2) | IL192119A (xx) |
NZ (1) | NZ569450A (xx) |
RU (1) | RU2433136C2 (xx) |
WO (1) | WO2007071051A1 (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101400793B (zh) * | 2005-12-21 | 2014-06-11 | 维文蒂阿生物技术股份有限公司 | 与癌症相关的新抗原 |
EP2282773B1 (en) | 2008-05-02 | 2014-01-15 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US9119818B2 (en) | 2008-05-14 | 2015-09-01 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
AU2013204721B2 (en) * | 2008-05-14 | 2016-08-18 | Agriculture Victoria Services Pty Ltd | Methods for treating cachexia |
DK2608796T3 (en) | 2010-08-05 | 2019-03-18 | Seattle Genetics Inc | Inhibition of protein fucosylation in vivo using fucose analogues |
AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
EP2887947B1 (en) | 2012-08-23 | 2019-06-05 | Seattle Genetics, Inc. | Fucose analogues for the treatment of sickle cell disease |
AU2014252683A1 (en) * | 2013-04-12 | 2015-11-19 | Viventia Bio Inc. | Compositions and methods for detection and treatment of hepatocellular carcinoma |
WO2014210036A1 (en) | 2013-06-24 | 2014-12-31 | Wilson Wolf Manufacturing Corporation | Closed system device and methods for gas permeable cell culture process |
US10745674B2 (en) * | 2014-03-06 | 2020-08-18 | Salk Institute For Biological Studies | Polyketide synthase variants and uses thereof |
TW202028222A (zh) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
US6670464B1 (en) * | 1998-11-17 | 2003-12-30 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
EA010803B1 (ru) * | 2004-03-19 | 2008-12-30 | Мерк Патент Гмбх | Модифицированные белки буганины, цитотоксины и способы их применения |
US20080213922A1 (en) * | 2005-04-04 | 2008-09-04 | Chahal Francina C | Method And System For Identification Of Antigen |
CN101400793B (zh) * | 2005-12-21 | 2014-06-11 | 维文蒂阿生物技术股份有限公司 | 与癌症相关的新抗原 |
-
2006
- 2006-12-21 CN CN200680053091.9A patent/CN101400793B/zh not_active Expired - Fee Related
- 2006-12-21 RU RU2008129770/10A patent/RU2433136C2/ru not_active IP Right Cessation
- 2006-12-21 CN CN201410210188.2A patent/CN104072611A/zh active Pending
- 2006-12-21 AU AU2006329198A patent/AU2006329198B2/en not_active Ceased
- 2006-12-21 WO PCT/CA2006/002101 patent/WO2007071051A1/en active Application Filing
- 2006-12-21 CA CA002633131A patent/CA2633131A1/en not_active Abandoned
- 2006-12-21 US US12/097,336 patent/US7956162B2/en active Active
- 2006-12-21 NZ NZ569450A patent/NZ569450A/en not_active IP Right Cessation
- 2006-12-21 ES ES06840528T patent/ES2395103T3/es active Active
- 2006-12-21 JP JP2008546058A patent/JP5380075B2/ja not_active Expired - Fee Related
- 2006-12-21 EP EP06840528A patent/EP1976987B1/en not_active Not-in-force
-
2008
- 2008-06-12 IL IL192119A patent/IL192119A/en not_active IP Right Cessation
-
2011
- 2011-04-26 US US13/094,118 patent/US8389286B2/en active Active
-
2013
- 2013-01-25 US US13/750,849 patent/US8946390B2/en active Active
- 2013-07-12 JP JP2013146257A patent/JP2014027932A/ja active Pending
- 2013-08-25 IL IL228116A patent/IL228116A/en not_active IP Right Cessation
-
2014
- 2014-12-18 US US14/575,007 patent/US20150297697A1/en not_active Abandoned
-
2015
- 2015-03-19 HK HK15102822.3A patent/HK1202299A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007071051A1 (en) | 2007-06-28 |
CN101400793A (zh) | 2009-04-01 |
US7956162B2 (en) | 2011-06-07 |
US20090305972A1 (en) | 2009-12-10 |
CN104072611A (zh) | 2014-10-01 |
EP1976987A1 (en) | 2008-10-08 |
US20130243799A1 (en) | 2013-09-19 |
AU2006329198B2 (en) | 2012-02-02 |
NZ569450A (en) | 2012-01-12 |
IL192119A (en) | 2015-04-30 |
IL228116A (en) | 2015-09-24 |
CA2633131A1 (en) | 2007-06-28 |
JP5380075B2 (ja) | 2014-01-08 |
JP2009520467A (ja) | 2009-05-28 |
IL192119A0 (en) | 2008-12-29 |
EP1976987A4 (en) | 2009-06-17 |
EP1976987B1 (en) | 2012-06-27 |
US20150297697A1 (en) | 2015-10-22 |
US8389286B2 (en) | 2013-03-05 |
US8946390B2 (en) | 2015-02-03 |
RU2008129770A (ru) | 2010-01-27 |
AU2006329198A1 (en) | 2007-06-28 |
RU2433136C2 (ru) | 2011-11-10 |
CN101400793B (zh) | 2014-06-11 |
JP2014027932A (ja) | 2014-02-13 |
ES2395103T3 (es) | 2013-02-08 |
US20120058106A1 (en) | 2012-03-08 |
IL228116A0 (en) | 2013-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218126A1 (zh) | 抗體 | |
HK1202299A1 (en) | Novel cancer-associated antigen | |
IL187106A (en) | Sclerostin binds antibody | |
IL190472A0 (en) | Anti-glypican-3 antibody | |
IL185366A0 (en) | Antibody | |
IL181575A0 (en) | Anti-ox40l antibodies | |
IL228033A0 (en) | Antibodies | |
GB0517487D0 (en) | Antibodies | |
ZA200709456B (en) | Anti-IL2 antibodies | |
GB0420466D0 (en) | Anti-glucan antibodies | |
ZA200701952B (en) | Anti-OX40L antibodies | |
EP2015785A4 (en) | ANTIGEN AGRM2 | |
EP1780221A4 (en) | ANTI-SYNOVIOLIN ANTIBODY | |
EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
GB0505489D0 (en) | Antibodies | |
GB0512278D0 (en) | Antibodies | |
GB0505054D0 (en) | Antibodies | |
GB0418415D0 (en) | Antibody | |
GB0420771D0 (en) | Antibody | |
GB0407587D0 (en) | Cancer associated antigens | |
GB0519883D0 (en) | Antibodies | |
GB0500400D0 (en) | Antibody | |
GB0413479D0 (en) | Novel antibodies | |
GB0402642D0 (en) | Antibodies | |
GB0402641D0 (en) | Antibodies |